WT1 and acute myeloid leukemia: Nine of the ten enrolled patients with RR-AML underwent complete analysis per-protocol set (PPS) and were evaluated in our phase I dose-escalation trial of aAVC-WT1 (Figures 1A and 1B; Table 1).